Affiliation:
1. Silesian Center for Heart Disease
2. University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital
3. Medical University of Silesia
4. National Institute of Hygiene
5. Medical University of Gdańsk
6. Jagiellonian University Medical College
7. Pomeranian Medical University
8. Medical University of Warsaw
Abstract
Abstract
Background:
Diabetes mellitus (DM) is a well-known risk factor for atrial fibrillation (AF), but the mechanism(s) by which DM affects AF prevalence remains unclear. This study aims to evaluate the impact of diabetes mellitus severity (expressed as its known duration), antihyperglycemic treatment regimen and glycaemic control on AF prevalence.
Methods:
From the representative sample of 3014 participants (mean age 77.5, 49.1% female) from the cross-sectional NOMED-AF study, 881 participants (mean age 77.6 ± 0.25, 46.4% female) with concomitant DM were involved in the analysis. AF was screened using a telemonitoring vest for a mean of 21.9 ± 9.1 days.
Results:
The mean DM duration was 12 ± 0.35 years, but no significant impact of DM timespan on AF prevalence was observed. No differences in the treatment pattern (oral medication vs insulin vs both oral + insulin) among the study population with and without AF were shown (p = 0.106). Metabolic control reflected by HbA1c levels showed no significant association with AF and silent AF prevalence (p = 0.635; p = 0.094). On multivariate analyses, age (Odds Ratio (OR) 1.35, 95%CI: 1.18-1.53, p<0.001), p=0.042), body mass index (BMI; OR 1.043, 95%CI: 1.01-1.08, p=0.027) and LDL<100 mg/dl (OR 0.64, 95%CI: 0.42-0.97, p=0.037) were independent risk factors for AF prevalence, while age (OR 1.45, 95%CI: 1.20-1.75, p<0.001), LDL<100 mg/dl (OR 0.43, 95%CI 0.23-0.82, p=0.011), use of statins (OR 0.51, 95%CI: 0.28-0.94, p=0.031) and HbA1c ≤6.5 (OR 0.46, 95%CI: 0.25-0.85, p=0.013) were associated with silent AF prevalence.
Conclusions:
Diabetes duration, diabetic treatment pattern or metabolic control per se did not significantly impact the prevalence of AF, including silent AF detected by prospective continuous monitoring. Independent predictors of AF were age, BMI and low LDL levels, with statins and HbA1c ≤6.5 being additional independent predictors for silent AF.
Trial registration: NCT03243474
Publisher
Research Square Platform LLC
Reference44 articles.
1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract [Internet]. Elsevier B.V.; 2018;138:271–81. Available from: https://doi.org/10.1016/j.diabres.2018.02.023
2. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, Alonso A. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J [Internet]. NIH Public Access; 2010 [cited 2019 Apr 17];159:850–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20435195
3. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: The atherosclerosis risk in communities (ARIC) study. Circulation [Internet]. 2011 [cited 2019 Jul 5];123:1501–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21444879
4. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease;Movahed MR;Int J Cardiol,2005
5. Tadic M, Cuspidi C. Type 2 diabetes mellitus and atrial fibrillation: From mechanisms to clinical practice [Internet]. Arch. Cardiovasc. Dis. 2015 [cited 2020 Mar 16]. p. 269–76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25858534